Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [2]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as January 5, 2023, to June 3, 2025 [2]. - Allegations include that the defendants downplayed inefficiencies arising from the integration and assured investors of their commitment to resolving these issues quickly [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of NEOG during the specified timeframe are encouraged to register for the class action by the deadline of September 16, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fiserv, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its Clover platform and the conversion of Payeezy merchants [1]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv forced Payeezy merchants to convert to its Clover platform due to cost issues and problems with the older Payeezy platform [1]. - Clover's revenue growth and gross payment volume (GPV) growth were temporarily inflated by these conversions, masking a slowdown in new merchant business [1]. - A significant number of former Payeezy merchants switched to competing solutions shortly after the conversion due to Clover's high pricing and inadequate customer service [1]. - As a result of losing these merchants, Clover's GPV growth significantly slowed, and its revenue growth became unsustainable [1]. - Fiserv's positive statements during the class period regarding Clover's growth strategies and business prospects were deemed materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is from July 24, 2024, to July 22, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is September 22, 2025, with no cost or obligation to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the strength and sustainability of Flywire's revenue growth was overstated; (2 ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of a weight loss drug, which has resulted in a significant drop in its stock price following the termination of a partnership with Novo Nordisk [1][4][5]. Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3]. Group 2: Legal Allegations - The class action lawsuit claims that during the class period from April 29, 2025, to June 23, 2025, Hims & Hers made false or misleading statements and failed to disclose material facts regarding its business practices [4]. - Specific allegations include the deceptive promotion and sale of illegitimate versions of Novo Nordisk's weight loss drug, Wegovy®, which posed risks to patient safety [4]. - The lawsuit also suggests that these actions led to a significant risk of termination of the collaboration with Novo Nordisk [4]. Group 3: Impact of the Lawsuit - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing the deceptive practices as the reason, which resulted in a more than 34% decline in Hims & Hers' stock price [5].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [3]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from January 5, 2023, to June 3, 2025 [3]. - Defendants allegedly downplayed inefficiencies arising from the integration and assured investors of their commitment to resolving these issues quickly [3]. - Shareholders are encouraged to register for the class action by the deadline of September 16, 2025, to potentially become lead plaintiffs [4]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 24, 2023, to May 14, 2025 [3]. - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the efficacy of BHV-7000 for bipolar disorder [3]. - The complaint claims that these misrepresentations are likely to have a significant negative impact on Biohaven's business and financial condition once revealed [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 12, 2025, to potentially be appointed as lead plaintiff [4]. - Registration will provide shareholders with portfolio monitoring software for status updates throughout the case [4]. Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its financial practices and operations, leading to significant stock price decline [1][4]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [3]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [3]. - The issues highlighted indicate weaknesses in Tempus' core operations and revenue prospects [3]. Group 2: Impact of Reports - On May 28, 2025, Spruce Point Capital Management issued a report raising multiple concerns about Tempus' management, operations, and financial reporting [4]. - The report pointed out that Tempus' actual AI capabilities may be overstated and that executives have ties to companies that have restated financial results [4]. - It also noted signs of aggressive accounting practices and issues with the AstraZeneca and Pathos AI deal that warrant further scrutiny [4]. - Following the release of this report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 [5].

Core Viewpoint - Over 10,000 European hotels have joined a collective lawsuit against Booking.com, seeking compensation for losses incurred due to a now-invalid clause that restricted competitive pricing [2][3]. Group 1: Lawsuit Details - The collective lawsuit targets Booking.com for damages from 2004 to 2024, claiming that the platform's clause put many hotels at a competitive disadvantage [2]. - The clause, which prohibited hotels from offering lower prices through their own or third-party channels, was ruled illegal by the European Court on September 19, 2024 [2]. - The deadline for hotels to join the lawsuit has been extended from July 31 to August 29 due to high demand for claims [3]. Group 2: Industry Impact - The lawsuit is supported by hotel industry associations from over 30 European countries, including Austria, Germany, Greece, and Italy [3]. - Despite dissatisfaction with Booking.com's practices, many hotels rely on the platform to expand their customer base [3]. - Booking.com holds a significant market share, accounting for 71% of the European market in 2023, with a notable decline in direct bookings from guests to hotels in recent years [3].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements to investors while concealing material adverse facts regarding the company's capital allocation priorities, particularly concerning its dividend strategy [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Organon securities between November 3, 2022, and April 30, 2025, with a deadline of July 22, 2025, for investors to apply as lead plaintiffs [2]. - The lawsuit claims that the defendants made overwhelmingly positive statements while hiding the true state of Organon's priorities, especially regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. Group 2: Stock Price Impact - Following the announcement of the lawsuit and the related disclosures, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [5]. Group 3: Investor Communication - Investors who suffered losses or have questions regarding their rights related to the lawsuit are encouraged to contact the law firm Bragar Eagel & Squire for more information [6].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations, leading to a significant drop in stock price [1][2]. Group 1: Allegations and Financial Impact - The class period for the allegations is from May 2, 2024, to May 6, 2025, during which Vestis Corporation allegedly provided overly positive statements while concealing material adverse facts about its business growth capabilities [2]. - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrew its revenue guidance for the full fiscal year, and provided lower-than-expected guidance for Q3 2025, attributing the poor performance to "lost business in excess of new business" and "lower adds over stops" [2]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by the deadline of August 8, 2025, to potentially become lead plaintiffs and receive updates on the case [3]. - Registration involves no cost or obligation, and participants will be enrolled in a portfolio monitoring system for status updates throughout the case lifecycle [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].